Dual-Targeted Therapy With Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD.
| Publicado en: | Gastroenterology & Hepatology Vol. 21; pp. 15 - 17 |
|---|---|
| Formato: | tables/charts Journal Article |
| Publicado: |
Gastro-Hep Communications, Inc
2025 Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188888829&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 188888829 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15547914 6N5B jtl: Gastroenterology & Hepatology issn: 15547914 maglogo: N pubinfo: dt: 2025 Supplement vid: 21 pid: 72163 pub: Gastro-Hep Communications, Inc place: New York, New York artinfo: ui: 188888829 188888829 188888829 188888829 ppf: 15 ppct: 2 formats: fmt: @attributes: type: P tig: atl: Dual-Targeted Therapy With Risankizumab and Upadacitinib Is Clinically and Biochemically Effective in Medically Complex CD. aug: sug: subj: Crohn Disease Drug Therapy Drug Therapy, Combination Antibodies, Monoclonal Therapeutic Use Heterocyclic Compounds Therapeutic Use Severity of Illness Treatment Outcomes Inflammation Drug Therapy Signal Transduction Drug Effects Biochemical Phenomena Adverse Drug Event Treatment Termination Drug Tolerance Disease Remission Patient Safety Drug Efficacy pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|